Mu-yan W. Cai
No. 58, ZhongShan Second Road
Zhongshan, 510080, China
Zhongshan, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications
Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2026
SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers.
Journal: Gut
Published: November 18, 2025
A deep learning model for the diagnosis of gastric neuroendocrine carcinoma.
Journal: Communications medicine
Published: August 30, 2025
A multimodal synergistic model for personalized neoadjuvant immunochemotherapy in esophageal cancer.
A multimodal synergistic model for personalized neoadjuvant immunochemotherapy in esophageal cancer.
Journal: Cell reports. Medicine
Published: July 15, 2025
BTAF1: a key regulator of DNA end resection and predictor of chemotherapy sensitivity in gastric cancer.
Journal: Cell death and differentiation
Published: May 29, 2025
TAOK1 promotes filament formation in HR repair through phosphorylating USP7.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 19, 2025
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Journal: Cell reports. Medicine
Published: January 14, 2025
Discussion on the relationship between pathological changes of sciatic nerve and Sarm1 protein expression in rats with n-hexane poisoning
Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
Published: September 02, 2024
Phase separation of ERCC6L2-CtIP regulates the extent of DNA end resection.
Journal: Nature cell biology
Published: August 16, 2024
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.
Journal: Signal transduction and targeted therapy
Published: July 30, 2024
Last Updated: 09/26/2026